This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Umberto Tirelli, MD; Domenico Errante, MD; Eric Oksenhendler, MD; Emanuela Vaccher, MD; Roberta Gastaldi, MD; Giuliano Rizzardini, MD; Silvio Monfardini, MD; Christian Gisselbrecht, MD
for the French-Italian Cooperative Study Group Aviana, Italy

JAMA. 1992;267(4):509.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Levine et al¹ have recently reported in JAMA that low-dose chemotherapy with central nervous system (CNS) prophylaxis and zidovudine maintenance did not compromise the therapeutic outcome of 42 patients with non-Hodgkin's lymphoma (NHL) related to the acquired immunodeficiency syndrome (AIDS). However, patients with poor prognosis, ie, those with low performance status and presence of opportunistic infections (OIs), were not eligible for entry into this study.

We in the French-Italian Cooperative Study Group have recently performed a prospective study in patients with poor-prognosis AIDS-related NHL, defined as those with performance status greater than 3 and/or presence of OIs. We used a low-dose chemotherapeutic regimen with CNS prophylaxis in combination with antiretroviral therapy, the aim being to reduce both the toxic effects on the bone marrow and the occurrence of OIs. The chemotherapeutic regimen employed was that used by the European Organization on Research and Treatment of . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?